Clinical Research Directory
Browse clinical research sites, groups, and studies.
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Sponsor: Reunion Neuroscience Inc
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Official title: A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-30
Completion Date
2026-12
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
Locations (25)
UAB, Psychiatry and Behavioral Neurology
Birmingham, Alabama, United States
University of Arizona
Tucson, Arizona, United States
Kadima Neuropsychiatry Institute
San Diego, California, United States
Providence Medical Foundation
Santa Rosa, California, United States
University of Colorado
Aurora, Colorado, United States
University of South Florida, Department of Psychiatry and Behavioral Neuroscience
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Hawaii Pacific Neuroscience
Honolulu, Hawaii, United States
Rush University Medical Center
Chicago, Illinois, United States
LSU Health Shreveport
Shreveport, Louisiana, United States
Sunstone Therapies, PC
Rockville, Maryland, United States
Sheppard Pratt
Towson, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Health
Novi, Michigan, United States
University of New Mexico, School of Medicine
Albuquerque, New Mexico, United States
NYU Langone Center for Psychedelic Medicine
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University, Department of Psychiatry
Columbus, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Alliance for Multispecialty Research Clinical
Knoxville, Tennessee, United States
Dell Medical School, University of Texas at Austin
Austin, Texas, United States
Cedar Clinical Research Inc.
Draper, Utah, United States
UVA Center for Psychiatric Clinical Research
Charlottesville, Virginia, United States
Seattle Neuropsychiatric Treatment Center
Seattle, Washington, United States